-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
-
Featured
Laterality of Renal Cell Carcinoma Predicts Survival in Certain Patient Subgroups
Patients with right-sided renal cell carcinoma are significantly more likely to have favorable clinicopathological features than patients with left-sided disease, and they have significantly better cancer-specific survival within certain subgroups.
-
Review: Checkpoint Inhibitors and Other Immunotherapies in Urologic Cancer
Aleksandra Walasek, MD, and Dimitar V. Zlatev, MD, discuss progress in immunotherapies for urologic cancers, showing checkpoint inhibitors are often first-line therapy, combination regimens are improving outcomes, and antibody–drug conjugates are becoming new options for dual-refractory bladder cancer.
-
Review: Biomarkers in Testicular Cancer
While classic serum tumor markers like α-fetoprotein and b-HCG are the gold standard for managing testicular germ cell tumors, microRNA are emerging as promising biomarkers with superior performance. Circulating tumor DNA and circulating tumor cells may prove to be important with further study.
-
Metabolomic Information Highly Useful for Predicting Future Prostate Cancer
Leo Cheng, PhD, and colleagues present evidence that metabolomic alterations detected with high-resolution magic angle spinning 1H nuclear magnetic resonance spectroscopy can differentiate between patients with benign prostate biopsies who will or will not receive a prostate cancer diagnosis over the following years.
Mass General Cancer Center Contributors
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Investigator, Center for Cancer Research, Mass General Cancer Center, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation -
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Massachusetts General Hospital, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
-
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic, Massachusetts General Hospital
Recent Article
New Research Supports Trimodality Therapy for Bladder Cancer
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
